- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00861588
Effects of Isoflavone in Patients With Watchful Waiting Benign Prostate Hyperplasia
March 12, 2009 updated by: Chinese University of Hong Kong
Benign prostatic hyperplasia (BPH) is a common problem among aging Caucasian men that produces significant morbidity and hea1th care costs.
It is likely that BPH is just as common among Chinese men.
Debate exists as to whether currently available surgical and pharmacological options for BPH are appropriate for men in the watchful-waiting stage of this condition.
Evidence suggests that the consumption of soy isoflavones is related to lower rates of BPH among Asian men.
The advantages of soy isoflavones over conventional therapies may include better patient compliance, improved safety and lower cost.
Despite the fact that soy isoflavones are safe and contain a health-conferring ingredient with a defined mechanism of action, no randomised control trial has been performed using isoflavones to treat BPH.
Therefore, a randomised control trial is proposed to test the tolerability and effectiveness of soy isoflavones (Soylife) verses placebo in 182 men with defined watchful waiting BPH over a period of 12 months.
In this trial, patients who fulfill the inclusion criteria, will either be given 40mg of soy isoflavones capsule (once daily) or a placebo capsule.
They will be reviewed every three months with maximal urine flow rate, international prostate symptoms score and quality of life measured.
Baseline tests include RFT, LFT, FBC, MSU, PSA and testosterone and to be repeated at 6th month and 12th month.
The investigators hypothesize that this intervention will reduce lower urinary tract symptoms and slow the progression of the disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
176
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hong Kong, Hong Kong
- The Chinese University of Hong Kong
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
43 years to 83 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Chinese ethnicity
- Age between 45-85 years
- Diagnosed to have watchful waiting BPH (Qmax< 15 ml/sec together with a voided volume of more than 150 mls)
- Not on any concurrent alternative medications for BPH
- Mentally capable to give informed written consent and willing to comply with study requirements
Exclusion Criteria:
- Prefers to have conventional medical or surgical treatment for BPH
- Concurrent treatment for unstable chronic diseases including unstable angina, poorly controlled DM (HbA1c >7.5), less than 3 months post-MI or frequent exacerbation of COPD (more than 3x in the last year)
- Known to have prostate cancer or kidney and/or liver failure
- Urinary symptoms due to known causes other than BPH including neurogenic bladder, urinary tract infection, bladder cancer, bladder stone, urethral stricture
- Previous history of prostatic surgery
- Illiterate or having difficulty in filling in a patient diary
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: isoflavones
Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive isoflavones
|
40mg of soy isoflavones capsule (once daily)
Other Names:
|
Placebo Comparator: starch
Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive placebo
|
starch placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary safety endpoint is tolerability i.e. discontinuation due to an adverse event. The primary efficacy outcome will be an improvement in the urine flow rate by at least 2ml/sec after 12 months treatment when compared to placebo.
Time Frame: 12 months
|
12 months
|
The secondary efficacy outcome measure will include an improvement in symptoms and quality of life measured in the International Prostate Symptom Score (IPSS) and Sf-36 respectively.
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The secondary efficacy outcome measure will include an improvement in symptoms and quality of life measured in IPSS and Sf-36 respectively.
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2006
Primary Completion (Actual)
September 1, 2007
Study Completion (Actual)
September 1, 2007
Study Registration Dates
First Submitted
March 12, 2009
First Submitted That Met QC Criteria
March 12, 2009
First Posted (Estimate)
March 13, 2009
Study Record Updates
Last Update Posted (Estimate)
March 13, 2009
Last Update Submitted That Met QC Criteria
March 12, 2009
Last Verified
March 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CUHK4453/05M
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Prostate Hyperplasia
-
Yonsei UniversityCompletedBPH( Benign Prostate Hyperplasia) | TURP(Transurethral Resection of Prostate)Korea, Republic of
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
San Carlo di Nancy HospitalElesta S.R.L.CompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy | Benign Prostatic Hypertrophy With Outflow Obstruction | Prostate HyperplasiaItaly
-
St. Luke's Medical Center, PhilippinesCompletedBenign Prostatic Hyperplasia | Prostate Cancer | ProstatitisPhilippines
-
Astellas Pharma IncCompletedBenign Prostate HyperplasiaJapan
-
Medi-Tate Ltd.CompletedBenign Prostate HyperplasiaUnited States, Canada
-
Shiraz University of Medical SciencesCompletedBenign Prostate HyperplasiaIran, Islamic Republic of
-
Diskapi Yildirim Beyazit Education and Research...UnknownBenign Prostate HyperplasiaTurkey
Clinical Trials on isoflavones (Soylife 25)
-
Baylor College of MedicineUniversity of Alabama at Birmingham; Texas A&M University; University of Georgia and other collaboratorsCompletedOsteoporosisUnited States
-
National Center for Complementary and Integrative...Completed
-
TNOEuropean Commission; Institut National de Recherche pour l'Agriculture, l'Alimentation... and other collaboratorsCompletedOsteoporosisNetherlands, France, Italy
-
Children's Hospital Medical Center, CincinnatiNational Cancer Institute (NCI)UnknownUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of Hawaii Cancer Research CenterNational Cancer Institute (NCI)CompletedBreast Cancer | Healthy, no Evidence of DiseaseUnited States
-
National Center for Complementary and Integrative...Completed
-
Thomas Jefferson UniversityJohnson & JohnsonCompletedMigraine HeadacheUnited States
-
The Archer-Daniels-Midland CompanyEurofins Dermscan PharmascanCompleted
-
Brigham and Women's HospitalCompleted
-
Iowa State UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed